CABGOLIN-0.5 inhibits prolactin secretion through dopamine receptor stimulation in the pituitary gland.
Recommended for:
Hyperprolactinemia in women and men
Restoration of ovulatory function and fertility
Prolactin-secreting pituitary adenomas
Suppression of lactation when medically indicated
Hyperprolactinemia, amenorrhoea, galactorrhoea, prolactinomas, infertility, medical suppression of lactation.
The tablets are taken orally once or twice a week, with the dosage individually adjusted based on prolactin levels and patient response.
Contraindications:
Arterial hypotension
Fibrotic heart conditions
Allergy to cabergoline or ergot derivatives
Pregnancy and breastfeeding (unless medically indicated)
Side Effects:
Nausea, headache
Dizziness, drowsiness
Constipation, low blood pressure
Sleep disturbances, depression